Cargando…
Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women
Osteoclasts are specialized cells that initiate the process of bone resorption, which has two phases, dissolution of the mineral component and degradation of the organic matrix, in which cathepsin K plays a key role. Cathepsin K inhibitors, which block the activity of cathepsin on bone resorption la...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951121/ https://www.ncbi.nlm.nih.gov/pubmed/20948576 http://dx.doi.org/10.4061/2010/401581 |
_version_ | 1782187690411687936 |
---|---|
author | Pérez-Castrillón, José Luis Pinacho, Florentino De Luis, Daniel Lopez-Menendez, María Dueñas Laita, Antonio |
author_facet | Pérez-Castrillón, José Luis Pinacho, Florentino De Luis, Daniel Lopez-Menendez, María Dueñas Laita, Antonio |
author_sort | Pérez-Castrillón, José Luis |
collection | PubMed |
description | Osteoclasts are specialized cells that initiate the process of bone resorption, which has two phases, dissolution of the mineral component and degradation of the organic matrix, in which cathepsin K plays a key role. Cathepsin K inhibitors, which block the activity of cathepsin on bone resorption lacunae, may be a new therapeutic option in osteoporosis. Odanacatib is a nonpeptidic biaryl inhibitor of cathepsin K. Two studies have evaluated the efficacy and safety of odanacatib, a phase I study to determine the dose and a phase II study of safety and efficacy. Due to the long half-life of odanacatib and the similar effects of different doses on bone remodeling markers, a weekly dosage was chosen for the phase II trail, with the best results being obtained with a dose of 50 mg. At 36 months, increases in bone mineral density similar to those produced by other powerful antiresorptive drugs (zoledronate and denosumab) were observed but there were differences in the behaviour of bone remodeling markers. Data on fractures from the phase III trial currently in development are required to confirm these possible advantages. |
format | Text |
id | pubmed-2951121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | SAGE-Hindawi Access to Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-29511212010-10-14 Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women Pérez-Castrillón, José Luis Pinacho, Florentino De Luis, Daniel Lopez-Menendez, María Dueñas Laita, Antonio J Osteoporos Review Article Osteoclasts are specialized cells that initiate the process of bone resorption, which has two phases, dissolution of the mineral component and degradation of the organic matrix, in which cathepsin K plays a key role. Cathepsin K inhibitors, which block the activity of cathepsin on bone resorption lacunae, may be a new therapeutic option in osteoporosis. Odanacatib is a nonpeptidic biaryl inhibitor of cathepsin K. Two studies have evaluated the efficacy and safety of odanacatib, a phase I study to determine the dose and a phase II study of safety and efficacy. Due to the long half-life of odanacatib and the similar effects of different doses on bone remodeling markers, a weekly dosage was chosen for the phase II trail, with the best results being obtained with a dose of 50 mg. At 36 months, increases in bone mineral density similar to those produced by other powerful antiresorptive drugs (zoledronate and denosumab) were observed but there were differences in the behaviour of bone remodeling markers. Data on fractures from the phase III trial currently in development are required to confirm these possible advantages. SAGE-Hindawi Access to Research 2010-06-14 /pmc/articles/PMC2951121/ /pubmed/20948576 http://dx.doi.org/10.4061/2010/401581 Text en Copyright © 2010 José Luis Pérez-Castrillón et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Pérez-Castrillón, José Luis Pinacho, Florentino De Luis, Daniel Lopez-Menendez, María Dueñas Laita, Antonio Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women |
title | Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women |
title_full | Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women |
title_fullStr | Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women |
title_full_unstemmed | Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women |
title_short | Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women |
title_sort | odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951121/ https://www.ncbi.nlm.nih.gov/pubmed/20948576 http://dx.doi.org/10.4061/2010/401581 |
work_keys_str_mv | AT perezcastrillonjoseluis odanacatibanewdrugforthetreatmentofosteoporosisreviewoftheresultsinpostmenopausalwomen AT pinachoflorentino odanacatibanewdrugforthetreatmentofosteoporosisreviewoftheresultsinpostmenopausalwomen AT deluisdaniel odanacatibanewdrugforthetreatmentofosteoporosisreviewoftheresultsinpostmenopausalwomen AT lopezmenendezmaria odanacatibanewdrugforthetreatmentofosteoporosisreviewoftheresultsinpostmenopausalwomen AT duenaslaitaantonio odanacatibanewdrugforthetreatmentofosteoporosisreviewoftheresultsinpostmenopausalwomen |